Month: January 2022
Excerpt from the Press Release: – First clinical combination study of BBP-398 and LUMAKRAS set to evaluate safety and preliminary efficacy in solid tumors with the KRAS G12C mutation PALO ALTO, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today…
Read More
ALARM Study Publication Shows Use of AlloSure for Home-Based, Non-invasive Surveillance Monitoring Can Provide a Safer Option for Lung Transplant Recipients Navigating the COVID-19 Pandemic Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization…
Read More
Excerpt from the Press Release: EMERYVILLE, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that the first patient has been dosed in the Phase 1/2 clinical trial of 4D-150 for neovascular age-related macular…
Read More
Portfolio includes five investigational gene therapy programs for glycogen storage disorders that have no existing FDA-approved treatments available Warden Bio Co-Founder Kunal Kishnani joins as President of Kriya’s Rare Disease Division and will lead its overall strategic, development, and partnership activities Excerpt from the Press Release: REDWOOD CITY, Calif. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Kriya…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Jan. 6, 2022 /PRNewswire/ — BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the closeout of the first of two cohorts in its ongoing Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease. The purpose of the Ph1 clinical trial…
Read More
ARROS-1 trial enrolling patients with advanced ROS1-positive NSCLC and other solid tumors Clinical development for parallel lead program, NVL-655, in ALK-positive cancers expected to begin in first half of 2022 Excerpt from the Press Release: CAMBRIDGE, Mass., Jan. 7, 2022 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in…
Read More
Clear Creek Bio signed a CRADA with the NIH to support its SARS-CoV-2 PLpro inhibitor discovery This CRADA was initiated as part of the Antiviral Program for Pandemics (APP) Via APP, Clear Creek will be able to use the NIH’s current and expanded contract resources and NCATS laboratories to prioritize the advancement of antiviral candidates…
Read More
Excerpt from the Press Release: REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of irreversible small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced today that BMF-219 displayed remarkable…
Read More
Excerpt from the Press Release: REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that the first patient has…
Read More
Excerpt from the Press Release: – 33% Objective Response Rate (ORR) was observed in 33 RECIST evaluable patients across all FolRα expression levels and both dose levels. – Dose response was observed, with a 47% ORR in 17 patients who started at the 5.2 mg/kg dose level. – Tumor proportion score (TPS) was selected as…
Read More